Mayumi Ueta Selected Research

EP3 Subtype Prostaglandin E Receptors

1/2021	Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications.
1/2020	Expression of prostaglandin E2 receptor 3 in the eyelid epidermis of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
11/2018	Results of Detailed Investigations Into Stevens-Johnson Syndrome With Severe Ocular Complications.
1/2015	HLA-A*02:06 and PTGER3 polymorphism exert additive effects in cold medicine-related Stevens-Johnson syndrome with severe ocular complications.
11/2012	Prostaglandin E2 suppresses poly I: C-stimulated cytokine production via EP2 and EP3 in immortalized human corneal epithelial cells.
1/2011	Prostaglandin E receptor subtype EP3 expression in human conjunctival epithelium and its changes in various ocular surface disorders.
12/2010	Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mayumi Ueta Research Topics

Disease

42	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2022 - 02/2007
20	Inflammation (Inflammations) 02/2021 - 09/2004
6	Dry Eye Syndromes (Dry Eye Syndrome) 01/2021 - 09/2013
5	Hypersensitivity (Allergy) 01/2019 - 02/2009
5	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 09/2013 - 02/2009
4	Asthma (Bronchial Asthma) 11/2010 - 05/2008
3	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021 - 01/2017
3	Atopic Dermatitis (Atopic Eczema) 01/2019 - 01/2016
3	Contact Dermatitis (Eczema, Contact) 11/2017 - 10/2009
3	Eye Burns (Eye Burn) 08/2014 - 01/2011
3	Benign Mucous Membrane Pemphigoid (Cicatricial Pemphigoid) 01/2012 - 11/2010
2	Cicatrix (Scar) 11/2020 - 01/2019
2	Virus Diseases (Viral Diseases) 11/2017 - 07/2007
2	Keratoconjunctivitis 01/2017 - 01/2014
2	Pterygium 08/2014 - 11/2010
2	Infections 11/2012 - 07/2007
1	Pain (Aches) 12/2020
1	Corneal Opacity 11/2020
1	Vision Disorders (Hemeralopia) 11/2020
1	Trichiasis 01/2020
1	Disease Susceptibility (Diathesis) 11/2019
1	Corneal Neovascularization 01/2019
1	Retinitis 12/2018
1	Anterior Uveitis 12/2018
1	Corneal Diseases (Corneal Disease) 12/2018
1	Atrophy 07/2018
1	Corneal Injuries 03/2016
1	Allergic Contact Dermatitis 02/2015
1	Skin Diseases (Skin Disease) 02/2015
1	Neoplasms (Cancer) 01/2015
1	gelatinous drop-like Corneal dystrophy 01/2015
1	Conjunctival Diseases 03/2014

Drug/Important Bio-Agent (IBA)

9	Toll-Like Receptor 3IBA 02/2021 - 07/2007
9	HLA-A Antigens (HLA-A)IBA 01/2021 - 02/2007
9	HLA-B Antigens (HLA-B)IBA 01/2021 - 11/2008
7	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 11/2012
7	EP3 Subtype Prostaglandin E ReceptorsIBA 01/2021 - 12/2010
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2010
5	rebamipideIBA 01/2021 - 09/2013
5	Ophthalmic Solutions (Eye Drops)IBA 01/2021 - 09/2013
5	Dinoprostone (PGE2)FDA Link 01/2020 - 11/2010
4	CytokinesIBA 11/2020 - 12/2010
4	Biomarkers (Surrogate Marker)IBA 11/2020 - 11/2013
4	Pharmaceutical PreparationsIBA 01/2019 - 09/2013
4	SteroidsIBA 07/2018 - 04/2009
4	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2017 - 07/2007
4	ProstaglandinsIBA 11/2012 - 02/2009
3	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2022 - 11/2015
3	AntigensIBA 01/2022 - 02/2015
3	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 06/2009
3	Immunoglobulin E (IgE)IBA 01/2017 - 08/2008
3	NF-kappa B (NF-kB)IBA 09/2010 - 09/2004
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021 - 01/2021
2	Multi-Ingredient Cold, Flu, and Allergy MedicationsIBA 01/2021 - 11/2018
2	Phenytoin (Dilantin)FDA LinkGeneric 01/2019 - 11/2013
2	Histocompatibility Antigens Class IIBA 01/2019 - 02/2007
2	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 09/2004
2	HLA-C Antigens (HLA-C)IBA 01/2018 - 01/2017
2	Picryl Chloride (Trinitrochlorobenzene)IBA 11/2017 - 02/2015
2	HaptensIBA 11/2017 - 10/2009
2	Allopurinol (Remid)FDA LinkGeneric 02/2016 - 11/2008
2	Carbamazepine (Tegretol)FDA LinkGeneric 01/2015 - 12/2010
2	Interleukin-8 (Interleukin 8)IBA 01/2014 - 09/2004
2	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 11/2010 - 02/2009
2	Antiviral Agents (Antivirals)IBA 11/2010 - 09/2010
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 11/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Dipyrone (Metamizole)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 10/2020
1	HLA-A*02:06:01 antigenIBA 11/2019
1	Cytochrome P-450 CYP2C9IBA 01/2019
1	Bevacizumab (Avastin)FDA Link 01/2019
1	Verteporfin (Visudyne)FDA Link 01/2019
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2019
1	Prednisolone (Predate)FDA LinkGeneric 01/2019
1	Fluorescein (Funduscein)FDA LinkGeneric 01/2018
1	OxazoloneIBA 11/2017
1	N 30IBA 01/2017
1	InterferonsIBA 01/2017
1	Arachidonic Acid (Vitamin F)IBA 01/2016
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2016
1	Ether (Diethyl Ether)IBA 01/2016
1	LipidsIBA 01/2016
1	Irritants (Vesicants)IBA 02/2015
1	CalciumIBA 01/2015
1	HLA-A31 antigenIBA 01/2015
1	Zonisamide (Zonegran)FDA LinkGeneric 11/2013
1	Phenobarbital (Luminal)FDA Link 11/2013
1	Anticonvulsants (Antiepileptic Drugs)IBA 11/2013
1	MucinsIBA 09/2013
1	LigandsIBA 11/2012
1	EP2 Subtype Prostaglandin E ReceptorsIBA 11/2012

Therapy/Procedure

6	Therapeutics 11/2021 - 06/2009
2	Contact Lenses 12/2020 - 11/2018
2	Transplantation 11/2020 - 03/2017
1	Eyeglasses (Spectacles) 12/2020
1	Aftercare (After-Treatment) 01/2019
1	Photochemotherapy (Photodynamic Therapy) 01/2019
1	Corneal Transplantation (Keratoplasty) 12/2018
1	Operative Surgical Procedures 03/2016